Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Waldemar Misiorowski

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Endokrynologia Polska|July 6, 2006
[Alendronate increases bone mineral density in patients with symptomatic primary hyperparathyroidism]Waldemar Misiorowski
Endokrynologia Polska|November 30, 2011
[Parathyroid hormone and its analogues - molecular mechanisms of action and efficacy of osteoporosis therapy]Waldemar Misiorowski
Endokrynologia Polska|March 3, 2011
Parathyroid hormone and its analogues--molecular mechanisms of action and efficacy in osteoporosis therapyWaldemar Misiorowski
Przeglad Menopauzalny = Menopause Review|July 20, 2017
Osteoporosis in menWaldemar Misiorowski
Endokrynologia Polska|June 30, 2017
Cinacalcet as symptomatic treatment of hypercalcaemia in primary hyperparathyroidism prior to surgeryWaldemar Misiorowski, Wojciech Zgliczyński
JBMR Plus|September 30, 2020
Osteitis Fibrosa CysticaWaldemar Misiorowski, John P Bilezikian
Endokrynologia Polska|April 28, 2009
Critical points in strategies for the diagnosis and treatment of osteoporosisRoman S Lorenc, Waldemar Misiorowski, Elzbieta Karczmarewicz
Neuro Endocrinology Letters|November 7, 2007
In acromegaly, increased bone mineral density (BMD) is determined by GH-excess, gonadal function and genderWojciech Zgliczynski, Magdalena Kochman, Waldemar Misiorowski, et al.
Polskie Archiwum Medycyny Wewnetrznej|April 4, 2014
Polish guidelines for the diagnosis and management of osteoporosis: a review of 2013 updatePiotr Głuszko, Roman S Lorenc, Elżbieta Karczmarewicz, et al.
Endocrine|September 14, 2017
Osteitis fibrosa cystica-a forgotten radiological feature of primary hyperparathyroidismWaldemar Misiorowski, Izabela Czajka-Oraniec, Magdalena Kochman, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Endokrynologia Polska|July 6, 2006
[Alendronate increases bone mineral density in patients with symptomatic primary hyperparathyroidism]Waldemar Misiorowski
Endokrynologia Polska|November 30, 2011
[Parathyroid hormone and its analogues - molecular mechanisms of action and efficacy of osteoporosis therapy]Waldemar Misiorowski
Endokrynologia Polska|March 3, 2011
Parathyroid hormone and its analogues--molecular mechanisms of action and efficacy in osteoporosis therapyWaldemar Misiorowski
Przeglad Menopauzalny = Menopause Review|July 20, 2017
Osteoporosis in menWaldemar Misiorowski
Endokrynologia Polska|June 30, 2017
Cinacalcet as symptomatic treatment of hypercalcaemia in primary hyperparathyroidism prior to surgeryWaldemar Misiorowski, Wojciech Zgliczyński
JBMR Plus|September 30, 2020
Osteitis Fibrosa CysticaWaldemar Misiorowski, John P Bilezikian
Endokrynologia Polska|April 28, 2009
Critical points in strategies for the diagnosis and treatment of osteoporosisRoman S Lorenc, Waldemar Misiorowski, Elzbieta Karczmarewicz
Neuro Endocrinology Letters|November 7, 2007
In acromegaly, increased bone mineral density (BMD) is determined by GH-excess, gonadal function and genderWojciech Zgliczynski, Magdalena Kochman, Waldemar Misiorowski, et al.
Polskie Archiwum Medycyny Wewnetrznej|April 4, 2014
Polish guidelines for the diagnosis and management of osteoporosis: a review of 2013 updatePiotr Głuszko, Roman S Lorenc, Elżbieta Karczmarewicz, et al.
Endocrine|September 14, 2017
Osteitis fibrosa cystica-a forgotten radiological feature of primary hyperparathyroidismWaldemar Misiorowski, Izabela Czajka-Oraniec, Magdalena Kochman, et al.
Pageof 3